NCT01526889View on ClinicalTrials.gov

Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 20, 2012

Primary Completion Date

February 16, 2017

Study Completion Date

August 24, 2017

Conditions
Non-infectious Intermediate UveitisNon-infectious Posterior UveitisNon-infectious Panuveitis
Interventions
DRUG

LFG316

LFG316 administered intravitreally (IVT)

DRUG

Conventional Therapy

Conventional Therapy administered in accordance with its prescribing info.

Trial Locations (8)

30060

Novartis Investigative Site, Marietta

77030

Novartis Investigative Site, Houston

80401

Novartis Investigative Site, Golden

02142

Novartis Investigative Site, Cambridge

68198-5540

Novartis Investigative Site, Omaha

07666

Novartis Investigative Site, Teaneck

BS1 2LX

Novartis Investigative Site, Bristol

EC1V 2PD

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY